Apogee Therapeutics Inc. (NASDAQ:APGE)’s traded shares stood at 0.33 million during the last session, with the company’s beta value hitting 2.86. At the close of trading, the stock’s price was $54.48, to imply a decrease of -4.17% or -$2.37 in intraday trading. The APGE share’s 52-week high remains $72.29, putting it -32.69% down since that peak but still an impressive 73.95% since price per share fell to its 52-week low of $14.19. The company has a valuation of $3.19B, with an average of 0.54 million shares in intraday trading volume over the past 10 days and average of 422.16K shares over the past 3 months.
Apogee Therapeutics Inc. (NASDAQ:APGE) trade information
After registering a -4.17% downside in the last session, Apogee Therapeutics Inc. (APGE) has traded red over the past five days. The 5-day price performance for the stock is -6.05%, and 12.94% over 30 days. With these gigs, the year-to-date price performance is 94.99%. Short interest in Apogee Therapeutics Inc. (NASDAQ:APGE) saw shorts transact 8.19 million shares and set a 22.9 days time to cover.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The extremes give us $95 and $95 for target low and target high price respectively. As such, APGE has been trading -74.38% off suggested target high and -74.38% from its likely low.
Apogee Therapeutics Inc. (APGE) estimates and forecasts
Looking at statistics comparing Apogee Therapeutics Inc. share performance against respective industry, we note that the company has outperformed competitors. Apogee Therapeutics Inc. (APGE) shares are -4.10% down over the last 6 months, with its year-to-date growth rate higher than industry average at 23.51% against 17.60%. Revenue is forecast to shrink -51.00% this quarter before falling -184.40% for the next one.
APGE Dividends
Apogee Therapeutics Inc. has its next earnings report out on 2024-Aug-12. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Apogee Therapeutics Inc. (NASDAQ:APGE)’s Major holders
Apogee Therapeutics Inc. insiders hold 11.31% of total outstanding shares, with institutional holders owning 122.88% of the shares at 138.56% float percentage. In total, 122.88% institutions holds shares in the company.
